Considering the high energy demands of neural oscillation, which are met by mitochondria, targeting Drp1 may emerge as a therapeutic strategy to prevent abnormal mitochondrion-related neurodegenerative diseases like Alzheimer’s disease (AD) and Parkinson’s disease (PD) [25]. The gene discussed is DNM1L; the disease is Parkinson disease.